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INTRODUCTION: Symptoms of severe intestinal dysmotility decrease patients’ quality of life and may
prevent them from sustaining adequate oral intake. Dronabinol is a synthetic cannabinoid that is labeled
for use in AIDS-related anorexia and chemotherapy-associated nausea and vomiting that has additional
efﬁcacy in patients with other etiologies of nausea, vomiting, and anorexia.
PRESENTATION OF CASE: We present a 58-year-old female with a history of nausea, vomiting, abdominal
pain, and inability to maintain oral intake after multiple laparotomies for ectopic pregnancy, recurrent
caecal volvulus, and cholecystitis. After eight years of unsuccessful trials of medicines, dietary modiﬁca-
tions, and a partial colectomy, she began a trial of dronabinol, which caused almost complete remission
of her symptoms. When this medication was discontinued by her payer, she was unable to maintain oral
intake and therefore, was admitted to the hospital for ﬂuid resuscitation and resumption of dronabinol.
DISCUSSION: The use of dronabinol in this patient with severe intestinal dysmotility allowed her to main-
tain her nutritional status orally and obviated the need for enteral or parenteral feeding. Unfortunately,
it was not covered by her insurance company for this indication.
CONCLUSION: Dronabinol has the potential to improve quality of life for patients beyond those under-
going chemotherapy or suffering from AIDS. Lack of access to this medicine for patients with intestinal
dysmotility after all other modalities have been tried can lead to morbid and expensive complications,
such as inpatient admission and surgery for enteral access.
© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Appropriate motility of the gastrointestinal tract requires func-
tioning of the musculature as well as the enteric, autonomic, and
somatic nervous systems. These systems can be perturbed by vari-
ous local or systemic insults, including but not limited to metabolic
derangements, degenerative neurological disease, spinal cord
injury, inﬁltrative disease, post-viral syndromes, and paraneoplas-
tic syndromes [1,2]. There are a number of disorders characterized
by symptoms of dysmotility—anorexia, nausea, vomiting, abdomi-
nal pain, distention, constipation, and/ordiarrhea—thatdonothave
clear etiologies, such as irritable bowel syndrome and functional
abdominal pain [3,4]. There is a wide range of medical treatments
for patients with these symptoms, including pro – and anti-kinetic
agents, anti-emetics, antidepressants, antibiotics, laxatives, and
other medicines.
Dronabinol is a synthetic cannabinoid that is thought to act
through endogenous cannabinoid receptors on multiple organ sys-
tems including the central and enteric nervous systems [5,6]. It
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has been established as an effective treatment for AIDS-associated
anorexia and chemotherapy-inducednausea [7–12]. It is frequently
used off-label for anorexia and nausea of other etiologies, but there
is a dearth of literature supporting its efﬁcacy in those settings.
Its anti-emetic mechanism of action is not completely understood,
although, it is thought to act both centrally andperipherally [13,14].
Data suggest that itmay slowgastric emptying and increase colonic
compliance in humans [15,16].
We present a case of a 58-year-old woman with debilitating
nausea, vomiting, and abdominal pain secondary to intestinal dys-
motility whose symptoms were refractory to medical treatment
with the exception of dronabinol.
2. Presentation of case
The patient is a 58 year-old woman who presented to multiple
health care providers over several years with symptoms of nau-
sea, vomiting, abdominal pain, and weight loss in the context of
reduced oral intake (Fig. 1). Her symptoms began in 2003, after
she presented to the emergency department of an outside hospital
with a caecal volvulus and underwent an exploratory laparotomy
with reduction of volvulus, lysis of adhesions, appendectomy, and
Meckel’s diverticulectomy. Her surgical history prior to this was
http://dx.doi.org/10.1016/j.ijscr.2015.04.036
2210-2612/© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. Timeline of patient’s pertinent medical and surgical history. Shaded areas represent presence of symptoms of abdominal pain, nausea, vomiting, and anorexia.
signiﬁcant for a laparotomy for ectopic pregnancy in 1985. After
the caecal volvulus surgery, the patient continued to experience
episodes every few months of intense, right-sided abdominal pain,
nausea, and vomiting. These symptoms progressed over the course
of a year into constant moderate nausea, more frequent episodes
of pain, and difﬁculty maintaining an appetite and oral intake.
Due to her symptoms, she was unable to continue her work in
the food service industry and applied for social security disabil-
ity insurance. In 2005, she underwent another laparotomy for
cholecystectomy during which extensive adhesions were found
and lysed. For approximately one year after this surgery, she was
symptom-free, but her intermittent “blockage” and near-constant
nausea returned.
Multiple etiologies for her symptomswere considered and then,
ruled out by additional work-up, including but not limited to dia-
betes mellitus, celiac disease, inﬂammatory bowel disease, and
connective tissue disease. In 2007, a two-hour gastric emptying
study showed markedly delayed gastric emptying. In addition, a
capsule study demonstrated luminal stenosis in the small bowel at
a site consistent with the location of her Meckel’s diverticulectomy
in 2003. In May 2008, she underwent a limited right colectomy to
treat her presumed recurrent small bowel obstructions at the site
of the stenosis. Following this operation, her symptoms diminished
considerablyuntilDecember2008,whensheagain felt a recurrence
in her nausea, vomiting, and abdominal pain.
Trials of metoclopramide, prochlorperazine, ondansetron,
erythromycin, tramadol, megestrol, multiple laxatives, omepra-
zole, tegaserod, and donnatal among other medicines were either
unsuccessful in abating the patient’s symptoms or had intolerable
side effects. Empiric treatment for possible bacterial overgrowth in
the small bowel was attempted with levoﬂoxacin and probiotics,
without effect. Various dietary modiﬁcations were explored, with
a low-fat, high-carbohydrate diet proving to be the most effective.
Regardless, the patient struggled to maintain a weight over 50kg
(BMI 18.4 kg/m2).
In 2011, a trial of 2.5mg of dronabinol twice a day was initiated.
Within a few months, the patient began to experience decreased
nausea and increased appetite. She denied any adverse effects, and
was able to consistently keep her weight above 50kg.
After the initiation of dronabinol, her course was largely
uneventful for several years. Her dose was titrated up to 5mg
four times a day, which sufﬁciently controlled her symptoms. In
May 2014, after a change in her insurance, she received a letter
from Medicare stating that her request for coverage of dronabinol
was denied, as its use in her case was not supported by the FDA
or Medicare-approved references. She presented to the outpatient
surgery clinic having been off dronabinol for several days, com-
plaining again of nausea, vomiting, abdominal pain, and inability
to tolerate oral intake “like from before.” At that time, she weighed
48kg (BMI of 17.6) with physical exam ﬁndings consistent with
dehydration. She was admitted directly to the hospital for failure
to thrive. While in the hospital, she was able to receive dronabinol
and experienced a marked remission in her symptoms. Since, she
has obtaineddronabinol from thehospital’s free care pharmacy and
has maintained her weight nearly 50kg.
Since their original denial, Medicare has denied three subse-
quent appeals to have dronabinol covered. The patient’s surgeon
was required to testify in front of an administrative judge, who
ruled in favor of the patient ﬁnding that the use of the drug in this
instancewasbasedon treating the same symptomsas the approved
indications. This was subsequently overturned by an administra-
tive oversight panel. The patient does not want symptoms typically
associated with marijuana and has rejected the notion of pursuing
this option now available in several states. Currently, the patient
is working with lawyers at the Medicare Advocacy Project in an
attempt to regain stable access to this medication.
3. Discussion
This patient presentedwith intestinal dysmotility of unclear eti-
ology. Gastric emptying studies indicate delayed gastric emptying,
but there is also an obstructive element that has been temporarily
alleviatedby lysis of adhesions and resection of the stenosedbowel.
Since, aswehavebeenunable to identify thepathophysiologic basis
of her disease, our strategyhas been to treat her symptoms. Shewas
unresponsive to many different medical therapies but responded
excellently to dronabinol, both subjectively in terms of her quality
of life and objectively in terms of her weight. Despite this dramatic
and consistent response, Medicare has rejected her requests and
appeals for coverage of this medicine. When she was admitted to
the hospital in 2014 for dehydration and failure to thrive, prompt
treatment with dronabinol prevented her from needed parenteral
or enteral nutrition.
Research identifying the possible uses of dronabinol is ongo-
ing, and as a result insurance policy is appropriately dynamic. For
example, recent evidence supporting the use of dronabinol for
Tourette syndrome has been cited in the Federal Register, result-
ing in approval for coverage for Tourette syndrome by some payers
[17]. Further research in the utility of dronabinol to treat symp-
toms of intestinal dysmotility is warranted, and may allow for both
better patient care and more appropriate insurance coverage.
4. Conclusion
Our experience with this demonstrates that dronabinol can
be an effective and well-tolerated treatment option for nausea,
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vomiting, and abdominal pain secondary to intestinal dysmotility
where other modalities have failed. The mechanism of action is
unclear, but is likely in the same family of etiologies of other estab-
lished indications. Lack of insurance coverage for dronabinol can
be a signiﬁcant barrier to care and necessitates continued research
to make the basis for policy in the future.
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